<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862459</url>
  </required_header>
  <id_info>
    <org_study_id>91400</org_study_id>
    <secondary_id>308200</secondary_id>
    <nct_id>NCT00862459</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)</brief_title>
  <official_title>Multi-center, Double-blind, Randomized, Controlled, Parallel Group, Dose Comparison Study With Corresponding Blinded Image Evaluation Following a Single Intravenous Injection of Three Different Doses of Gadobutrol 1.0 Molar (Gadavist) in Patients With Known or Suspected Focal Blood Brain Barrier Disturbances and/or Abnormal Vascularity of the Central Nervous System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety (what are the side effects) and efficacy
      (how well does it work) of Gadavist when used for taking images of the brain and spine. The
      results of the MRI with Gadavist Injection will be compared to the results of MR images taken
      without contrast and with the results of the MR images taken with OptiMARK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety issues are addressed in the Adverse Events section
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Categorical Visualization Score (CVS)</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The primary visualization variables (number [no.] of lesions detected, border delineation, contrast enhancement, internal morphology) were condensed to a composite score (CVS). Each variable was considered a category; the CVS was calculated as: CVS=(No. of categories with increase over precontrast)-(No. of categories with decrease over precontrast). The possible outcomes of the CVS for a participant and each reader were in the range of - 3 to +4. The CVS was averaged across the 3 blinded readers, producing 1 mean CVS per participant. The higher the CVS, the more effective the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>Three blinded readers evaluated the unenhanced MRI sets and the combined unenhanced/gadobutrol-enhanced MRI sets to evaluate the number of lesions, which was then averaged to produce an average reader value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Lesion Contrast Enhancement</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded readers assessed the degree of contrast enhancement for each lesion on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement, which was then averaged to produce an average reader score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Border Delineation</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded readers assessed the delineation for each lesion on a 4-point scale where 1 = none and 4 = excellent, which was then averaged to produce an average reader score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Internal Morphology</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded readers assessed the degree of information available about internal morphology and structure for each lesion on a 3-point scale where 1 = poor and 3 = good, which was then averaged to produce an average reader score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>CNR between white and gray matter in the perfusion imaging was defined as the signal intensity (SI) difference between white and gray matter divided by the standard deviation of the SI of white matter. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for blinded reader (BR) 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Lesions: Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy Comparison of Gadobutrol Doses - Detection of Matched Enhanced Lesions: Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Correct Diagnosis Following Gadobutrol-enhanced and Unenhanced MRI</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The gadobutrol-enhanced and unenhanced MRI diagnoses of the average reader were compared to the final diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Diagnostic Confidence Based on Unenhanced MRI and Combined Unenhanced and Enhanced MRI</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The diagnostic confidence, the level of certainty in a diagnosis, was determined based on the average of the blinded readers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume [CBV]) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Permeability Factor (PF) - Blinded Reader 1</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 1 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Permeability Factor (PF) - Blinded Reader 2</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 2 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Quality (Permeability Factor (PF)) - Blinded Reader 3</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>BR 3 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Uncorrected Cerebral Blood Volume (CBV)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the uncorrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Corrected Cerebral Blood Volume (CBV)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the corrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Cerebral Blood Flow (CBF)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the CBF for each lesion. CBF is the volume of blood passing through tissue per unit of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Time to Peak (TTP)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the TTP for each lesion. TTP is the delay between the arrival of the contrast agent bolus arrival time and the peak of the concentration curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Mean Transit Time (MTT)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the MTT for each lesion. The MTT is the time (seconds) for contrast to pass through tissues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Parameter Value (Permeability Factor (PF)) - Independent Radiologist</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The independent radiologist determined the PF for each lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Uncorrected Cerebral Blood Volume (CBV)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the uncorrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Corrected Cerebral Blood Volume (CBV)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the corrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time. CBV is the fraction of the tissue volume occupied by the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Cerebral Blood Flow (CBF)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the CBF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Time to Peak (TTP)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the TTP perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Mean Transit Time (MTT)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the MTT perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Perfusion Map Artifacts (Permeability Factor (PF)) - Blinded Reader</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded reader evaluated if artifacts were present on the PF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of MRI Tumor Grade Agreement With Biopsy Results by Dose Group</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>The blinded readers gave an estimation of the tumor grade of brain tumors (low grade [I or II] or high grade [III or IV]) in terms of malignancy using the information obtained by perfusion imaging, which was compared to the biopsy sample results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast to Noise Ratio (CNR) of Lesion/Gray Matter and Lesion/White Matter</measure>
    <time_frame>up to 2 hours after the injection of study medication</time_frame>
    <description>CNR between lesion/gray matter and lesion/white matter in the perfusion imaging was defined as the signal intensity (SI) difference between lesion and gray or white matter divided by the standard deviation of background noise. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Brain Diseases</condition>
  <condition>Spinal Cord Diseases</condition>
  <arm_group>
    <arm_group_label>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)</intervention_name>
    <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
    <arm_group_label>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)</intervention_name>
    <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
    <arm_group_label>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)</intervention_name>
    <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
    <arm_group_label>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OptiMARK~0.1 mmol/kg BW</intervention_name>
    <description>Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
    <arm_group_label>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
    <arm_group_label>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
    <arm_group_label>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with either known or highly suspected focal areas of disruption of the blood
             brain barrier (BBB) (eg, primary and secondary tumors, focal inflammatory or
             demyelinating disorders) and/or abnormal vascularity in the CNS, who are scheduled to
             undergo a routine contrast-enhanced MRI of the CNS.

          -  Patients with untreated brain tumors should constitute a minimum of 50% of the study
             population and patients with treated brain tumors will be limited to a maximum of 20%
             of the study population

        Exclusion Criteria:

          -  Is a female patient who is pregnant or nursing.

          -  Is a female of childbearing potential and did not have a negative urine pregnancy test
             the same day as the administration of gadobutrol or comparator treatment.

          -  Has received any investigational product within 30 days prior to enrolling in this
             study.

          -  Has been previously enrolled in this study or any other study using gadobutrol.

          -  Has any contraindication to the MRI examinations.

          -  Has a history of severe allergic or anaphylactoid reaction to any allergen including
             drugs and contrast agents.

          -  Has received any contrast agent within 24 hours prior to gadobutrol contrast
             administration, or is scheduled to receive any contrast agent within 72 hours after
             the gadobutrol study.

          -  Is considered to be clinically unstable or his/her clinical course during the study
             period is unpredictable (eg, due to previous surgery, acute renal failure).

          -  Has been treated with high dose (&gt;55 cobalt Gy equivalent) photon radiation or global
             radiotherapy for CNS lesions at any time before entering the study.

          -  Is scheduled to receive chemotherapy or radiotherapy during the study period.

          -  Is expected or scheduled to have a change in any treatment or procedure between the
             comparator and gadobutrol MRIs that may alter their interpretation.

          -  Is scheduled or is likely to require a biopsy or surgery within the 72 hours after the
             gadobutrol MRI procedure, or is scheduled for or has undergone such interventions
             between the comparator and gadobutrol studies.

          -  Has severe cardiovascular disease.

          -  Has any contraindication to OptiMARK according to the package insert.

          -  Has more than 30 brain lesions detected by any prior imaging examination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Jacksonville Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Neuroscience Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Le Bonheur Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cientifica del Sur</name>
      <address>
        <city>Lornas de Zamora</city>
        <state>Buenos Aires</state>
        <zip>B1832BQS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TCba Salguero</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Beneficiência Portuguesa</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico Medico</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto de Alta tecnología médica de Antioquia</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIME Clinica Neurocardiovascular S.A.</name>
      <address>
        <city>Cali</city>
        <state>Valle del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Clínica Valle del Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2009</study_first_posted>
  <results_first_submitted>September 14, 2011</results_first_submitted>
  <results_first_submitted_qc>December 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The date of the first participant's first visit was 27 August 2005. The date of the last participant's last visit was 26 March 2007.</recruitment_details>
      <pre_assignment_details>242 participants were screened: 5 were screening failures (withdrew consent, did not meet study criteria, other). The remaining 237 were randomized to the 0.3, 0.1, or 0.03 millimole per kilogram (mmol/kg) group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.03 mmol/kg body weight (BW) of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 milliliter per second (mL/s) followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="P2">
          <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="P3">
          <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="70">Number reflects all treated participants of whom 67 received Gadobutrol and 70 received OptiMARK</participants>
                <participants group_id="P2" count="90">Number reflects all treated participants of whom 90 received Gadobutrol and 88 received OptiMARK</participants>
                <participants group_id="P3" count="69">Number reflects all treated participants of whom 68 received Gadobutrol and 69 received OptiMARK</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Operation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intravenous (IV) site problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to hold still for imaging</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.03 millimole per kilogram of body weight (mmol/kg BW) of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 milliliter per second (mL/s) followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="B2">
          <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="B3">
          <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Categorical Visualization Score (CVS)</title>
        <description>The primary visualization variables (number [no.] of lesions detected, border delineation, contrast enhancement, internal morphology) were condensed to a composite score (CVS). Each variable was considered a category; the CVS was calculated as: CVS=(No. of categories with increase over precontrast)–(No. of categories with decrease over precontrast). The possible outcomes of the CVS for a participant and each reader were in the range of - 3 to +4. The CVS was averaged across the 3 blinded readers, producing 1 mean CVS per participant. The higher the CVS, the more effective the treatment.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>The per protocol set (PPS), which included all participants with valid images who received +/-10% of the intended dose of study drug and had no major protocol or Magnetic Resonance Imaging (MRI) procedure deviations (excluding one participant with insufficient images)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Visualization Score (CVS)</title>
          <description>The primary visualization variables (number [no.] of lesions detected, border delineation, contrast enhancement, internal morphology) were condensed to a composite score (CVS). Each variable was considered a category; the CVS was calculated as: CVS=(No. of categories with increase over precontrast)–(No. of categories with decrease over precontrast). The possible outcomes of the CVS for a participant and each reader were in the range of - 3 to +4. The CVS was averaged across the 3 blinded readers, producing 1 mean CVS per participant. The higher the CVS, the more effective the treatment.</description>
          <population>The per protocol set (PPS), which included all participants with valid images who received +/-10% of the intended dose of study drug and had no major protocol or Magnetic Resonance Imaging (MRI) procedure deviations (excluding one participant with insufficient images)</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.07"/>
                    <measurement group_id="O2" value="2.02" spread="1.04"/>
                    <measurement group_id="O3" value="1.98" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 sample t-test between the dose groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.59</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.59</dispersion_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.</title>
        <description>Three blinded readers evaluated the unenhanced MRI sets and the combined unenhanced/gadobutrol-enhanced MRI sets to evaluate the number of lesions, which was then averaged to produce an average reader value.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding one participant with insufficient images)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI.</title>
          <description>Three blinded readers evaluated the unenhanced MRI sets and the combined unenhanced/gadobutrol-enhanced MRI sets to evaluate the number of lesions, which was then averaged to produce an average reader value.</description>
          <population>PPS (excluding one participant with insufficient images)</population>
          <units>Lesions per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.82"/>
                    <measurement group_id="O2" value="0.04" spread="2.28"/>
                    <measurement group_id="O3" value="0.09" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.069</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.825</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Lesion Contrast Enhancement</title>
        <description>The blinded readers assessed the degree of contrast enhancement for each lesion on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement, which was then averaged to produce an average reader score.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Lesion Contrast Enhancement</title>
          <description>The blinded readers assessed the degree of contrast enhancement for each lesion on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement, which was then averaged to produce an average reader score.</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.93"/>
                    <measurement group_id="O2" value="1.78" spread="1.07"/>
                    <measurement group_id="O3" value="1.79" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Border Delineation</title>
        <description>The blinded readers assessed the delineation for each lesion on a 4-point scale where 1 = none and 4 = excellent, which was then averaged to produce an average reader score.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Border Delineation</title>
          <description>The blinded readers assessed the delineation for each lesion on a 4-point scale where 1 = none and 4 = excellent, which was then averaged to produce an average reader score.</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.60"/>
                    <measurement group_id="O2" value="0.68" spread="0.61"/>
                    <measurement group_id="O3" value="0.70" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.619</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Internal Morphology</title>
        <description>The blinded readers assessed the degree of information available about internal morphology and structure for each lesion on a 3-point scale where 1 = poor and 3 = good, which was then averaged to produce an average reader score.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Internal Morphology</title>
          <description>The blinded readers assessed the degree of information available about internal morphology and structure for each lesion on a 3-point scale where 1 = poor and 3 = good, which was then averaged to produce an average reader score.</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.50"/>
                    <measurement group_id="O2" value="0.90" spread="0.57"/>
                    <measurement group_id="O3" value="0.80" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI</title>
        <description>CNR between white and gray matter in the perfusion imaging was defined as the signal intensity (SI) difference between white and gray matter divided by the standard deviation of the SI of white matter. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding participants with insufficient images)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI</title>
          <description>CNR between white and gray matter in the perfusion imaging was defined as the signal intensity (SI) difference between white and gray matter divided by the standard deviation of the SI of white matter. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
          <population>PPS (excluding participants with insufficient images)</population>
          <units>CNR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="11.4"/>
                    <measurement group_id="O2" value="27.0" spread="75.6"/>
                    <measurement group_id="O3" value="22.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>difference in CNR between doses and confidence interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>76.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-37.11</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>77.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.86</ci_lower_limit>
            <ci_upper_limit>25.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 1</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for blinded reader (BR) 1.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 1</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for blinded reader (BR) 1.</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.58"/>
                    <measurement group_id="O2" value="65.24"/>
                    <measurement group_id="O3" value="54.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Chi-squared</method>
            <method_desc>Adjusted for clustering</method_desc>
            <param_type>accuracy difference</param_type>
            <param_value>1.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.93</ci_lower_limit>
            <ci_upper_limit>14.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracies</param_type>
            <param_value>-10.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.41</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 2</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 2</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 2</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 2</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.62"/>
                    <measurement group_id="O2" value="71.05"/>
                    <measurement group_id="O3" value="57.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>13.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>25.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracies</param_type>
            <param_value>-13.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.07</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 3</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 3</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Lesions: Blinded Reader 3</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched lesions was performed for BR 3</description>
          <population>PPS (excluding subjects with no lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.31"/>
                    <measurement group_id="O2" value="57.18"/>
                    <measurement group_id="O3" value="50.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>-6.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.73</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracies</param_type>
            <param_value>2.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.59</ci_lower_limit>
            <ci_upper_limit>12.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 1</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 1</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no enhanced lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 1</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 1</description>
          <population>PPS (excluding subjects with no enhanced lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.10"/>
                    <measurement group_id="O2" value="72.73"/>
                    <measurement group_id="O3" value="55.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>24.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.39</ci_lower_limit>
            <ci_upper_limit>43.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>-10.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.41</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 2</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 2</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects with no enhanced lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 2</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 2</description>
          <population>PPS (excluding subjects with no enhanced lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.23"/>
                    <measurement group_id="O2" value="82.14"/>
                    <measurement group_id="O3" value="63.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>12.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>27.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>-18.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-33.60</ci_lower_limit>
            <ci_upper_limit>-1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 3</title>
        <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 3</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS(excluding subjects with no enhanced lesion detected)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy Comparison of Gadobutrol Doses – Detection of Matched Enhanced Lesions: Blinded Reader 3</title>
          <description>The percent accuracy (total number of lesions matching the comparator divided by the total number of lesions identified by gadobutrol) comparison of the 0.03 and 0.1 mmol/kg gadobutrol doses and the 0.1 and 0.3 mmol/kg gadobutrol doses using detection of all comparator-detected matched enhanced lesions was performed for BR 3</description>
          <population>PPS(excluding subjects with no enhanced lesion detected)</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.07"/>
                    <measurement group_id="O2" value="73.53"/>
                    <measurement group_id="O3" value="68.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>18.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.15</ci_lower_limit>
            <ci_upper_limit>33.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Chi-squared</method>
            <method_desc>adjusted for clustering</method_desc>
            <param_type>difference in accuracy</param_type>
            <param_value>-5.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.83</ci_lower_limit>
            <ci_upper_limit>8.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Correct Diagnosis Following Gadobutrol-enhanced and Unenhanced MRI</title>
        <description>The gadobutrol-enhanced and unenhanced MRI diagnoses of the average reader were compared to the final diagnosis.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Correct Diagnosis Following Gadobutrol-enhanced and Unenhanced MRI</title>
          <description>The gadobutrol-enhanced and unenhanced MRI diagnoses of the average reader were compared to the final diagnosis.</description>
          <population>PPS</population>
          <units>percentage of exact matches</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Diagnostic Confidence Based on Unenhanced MRI and Combined Unenhanced and Enhanced MRI</title>
        <description>The diagnostic confidence, the level of certainty in a diagnosis, was determined based on the average of the blinded readers.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS, Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Diagnostic Confidence Based on Unenhanced MRI and Combined Unenhanced and Enhanced MRI</title>
          <description>The diagnostic confidence, the level of certainty in a diagnosis, was determined based on the average of the blinded readers.</description>
          <population>PPS, Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>not confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>somewhat confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>very confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume [CBV]) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS, Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume [CBV]) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
          <population>PPS, Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Applicable (Appl.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
          <population>PPS. Due to rounding, the sum of percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the uncorrected CBV perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the corrected CBV perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Cerebral Blood Flow (CBF)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the CBF perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Time to Peak (TTP)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the TTP perfusion map.</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Mean Transit Time (MTT)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the MTT perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 1</title>
        <description>BR 1 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 1</title>
          <description>BR 1 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 2</title>
        <description>BR 2 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF) – Blinded Reader 2</title>
          <description>BR 2 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
          <population>PPS. Due to rounding, the sum of the percentages may range from 99.9 to 100.1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF)) – Blinded Reader 3</title>
        <description>BR 3 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Quality (Permeability Factor (PF)) – Blinded Reader 3</title>
          <description>BR 3 evaluated the visibility of the lesion(s) on the PF perfusion map.</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Appl.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not visible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Uncorrected Cerebral Blood Volume (CBV)) – Independent Radiologist</title>
        <description>The independent radiologist determined the uncorrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Uncorrected Cerebral Blood Volume (CBV)) – Independent Radiologist</title>
          <description>The independent radiologist determined the uncorrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>mL / 100 g tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.61" spread="127.75"/>
                    <measurement group_id="O2" value="346.81" spread="313.49"/>
                    <measurement group_id="O3" value="1209.89" spread="1121.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Corrected Cerebral Blood Volume (CBV)) – Independent Radiologist</title>
        <description>The independent radiologist determined the corrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Corrected Cerebral Blood Volume (CBV)) – Independent Radiologist</title>
          <description>The independent radiologist determined the corrected CBV for each lesion. CBV is the volume of blood in the tissue.</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>mL / 100 g tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2728.71" spread="2788.59"/>
                    <measurement group_id="O2" value="2682.97" spread="1493.95"/>
                    <measurement group_id="O3" value="3382.20" spread="1908.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Cerebral Blood Flow (CBF)) – Independent Radiologist</title>
        <description>The independent radiologist determined the CBF for each lesion. CBF is the volume of blood passing through tissue per unit of time.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Cerebral Blood Flow (CBF)) – Independent Radiologist</title>
          <description>The independent radiologist determined the CBF for each lesion. CBF is the volume of blood passing through tissue per unit of time.</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>mL / 100 g tissue / min.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="6.37"/>
                    <measurement group_id="O2" value="5.15" spread="4.30"/>
                    <measurement group_id="O3" value="3.48" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Time to Peak (TTP)) – Independent Radiologist</title>
        <description>The independent radiologist determined the TTP for each lesion. TTP is the delay between the arrival of the contrast agent bolus arrival time and the peak of the concentration curve.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Time to Peak (TTP)) – Independent Radiologist</title>
          <description>The independent radiologist determined the TTP for each lesion. TTP is the delay between the arrival of the contrast agent bolus arrival time and the peak of the concentration curve.</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.39" spread="25.43"/>
                    <measurement group_id="O2" value="80.31" spread="27.21"/>
                    <measurement group_id="O3" value="86.52" spread="28.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Mean Transit Time (MTT)) – Independent Radiologist</title>
        <description>The independent radiologist determined the MTT for each lesion. The MTT is the time (seconds) for contrast to pass through tissues.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Mean Transit Time (MTT)) – Independent Radiologist</title>
          <description>The independent radiologist determined the MTT for each lesion. The MTT is the time (seconds) for contrast to pass through tissues.</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.30" spread="4.77"/>
                    <measurement group_id="O2" value="6.02" spread="3.71"/>
                    <measurement group_id="O3" value="7.05" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Parameter Value (Permeability Factor (PF)) – Independent Radiologist</title>
        <description>The independent radiologist determined the PF for each lesion</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects whose parameter map value was not determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Parameter Value (Permeability Factor (PF)) – Independent Radiologist</title>
          <description>The independent radiologist determined the PF for each lesion</description>
          <population>PPS (excluding subjects whose parameter map value was not determined)</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="3.35"/>
                    <measurement group_id="O2" value="1.65" spread="0.82"/>
                    <measurement group_id="O3" value="0.99" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the uncorrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Uncorrected Cerebral Blood Volume (CBV)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the uncorrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time.</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded reader 2 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="66.1"/>
                    <measurement group_id="O3" value="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the corrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time. CBV is the fraction of the tissue volume occupied by the blood.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Corrected Cerebral Blood Volume (CBV)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the corrected CBV perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time. CBV is the fraction of the tissue volume occupied by the blood.</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="76.8"/>
                    <measurement group_id="O3" value="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7"/>
                    <measurement group_id="O2" value="80.4"/>
                    <measurement group_id="O3" value="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7"/>
                    <measurement group_id="O2" value="69.6"/>
                    <measurement group_id="O3" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Cerebral Blood Flow (CBF)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the CBF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Cerebral Blood Flow (CBF)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the CBF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2- Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2- 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="82.1"/>
                    <measurement group_id="O3" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2- movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2- other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9"/>
                    <measurement group_id="O2" value="76.8"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Time to Peak (TTP)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the TTP perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Time to Peak (TTP)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the TTP perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4"/>
                    <measurement group_id="O2" value="76.8"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1- movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Mean Transit Time (MTT)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the MTT perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Mean Transit Time (MTT)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the MTT perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="66.1"/>
                    <measurement group_id="O3" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Perfusion Map Artifacts (Permeability Factor (PF)) – Blinded Reader</title>
        <description>The blinded reader evaluated if artifacts were present on the PF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Perfusion Map Artifacts (Permeability Factor (PF)) – Blinded Reader</title>
          <description>The blinded reader evaluated if artifacts were present on the PF perfusion map and recorded the type of the major artifact. EPI: echo-planar imaging; T2: transversal relaxation time</description>
          <population>PPS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 1 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - 0 none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="51.8"/>
                    <measurement group_id="O3" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - EPI distortion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - T2 artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="10.7"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - movement artifacts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3 - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of MRI Tumor Grade Agreement With Biopsy Results by Dose Group</title>
        <description>The blinded readers gave an estimation of the tumor grade of brain tumors (low grade [I or II] or high grade [III or IV]) in terms of malignancy using the information obtained by perfusion imaging, which was compared to the biopsy sample results</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS participants with tumors</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of MRI Tumor Grade Agreement With Biopsy Results by Dose Group</title>
          <description>The blinded readers gave an estimation of the tumor grade of brain tumors (low grade [I or II] or high grade [III or IV]) in terms of malignancy using the information obtained by perfusion imaging, which was compared to the biopsy sample results</description>
          <population>PPS participants with tumors</population>
          <units>Percentage of accuracy</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blinded Reader 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinded Reader 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contrast to Noise Ratio (CNR) of Lesion/Gray Matter and Lesion/White Matter</title>
        <description>CNR between lesion/gray matter and lesion/white matter in the perfusion imaging was defined as the signal intensity (SI) difference between lesion and gray or white matter divided by the standard deviation of background noise. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
        <time_frame>up to 2 hours after the injection of study medication</time_frame>
        <population>PPS (excluding subjects who had no lesion detected, and those who had no value determined)</population>
        <group_list>
          <group group_id="O1">
            <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O2">
            <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
          <group group_id="O3">
            <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
            <description>Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
          </group>
        </group_list>
        <measure>
          <title>Contrast to Noise Ratio (CNR) of Lesion/Gray Matter and Lesion/White Matter</title>
          <description>CNR between lesion/gray matter and lesion/white matter in the perfusion imaging was defined as the signal intensity (SI) difference between lesion and gray or white matter divided by the standard deviation of background noise. An independent radiologist evaluated the gadobutrol-enhanced perfusion MRI for signal intensity.</description>
          <population>PPS (excluding subjects who had no lesion detected, and those who had no value determined)</population>
          <units>CNR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>lesion gray</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="13.0"/>
                    <measurement group_id="O2" value="13.0" spread="78.4"/>
                    <measurement group_id="O3" value="5.38" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lesion white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="12"/>
                    <measurement group_id="O2" value="-17" spread="19.9"/>
                    <measurement group_id="O3" value="-17" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Reporting Group 1 (RG1): Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="E2">
          <title>Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Reporting group 2 (RG2): Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="E3">
          <title>Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)</title>
          <description>Reporting group 3 (RG3): Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
        <group group_id="E4">
          <title>Optimark~0.1mmol/kg BW</title>
          <description>Reporting group 4 (RG4): Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Galactorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of results will be a group publication. Sites with recruitment of &gt;= 6 valid patients will contribute. There will be one author from each site having contributed &gt;= 6 valid patients. Authorship listed according to recruitment. Sponsor will appoint up to 3 persons as co-authors. Main author of publication may be announced by site with most valid patients enrolled. In case more than 1 center reaches maximum patient No., main author will be from the center with fastest recruitment</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>OptiMARK was used as a standard of reference in this study. A formal comparison of the efficacy of gadobutrol and OptiMARK was not specified prospectively in the statistical analysis plan. For completeness, the safety data of OptiMARK is presented.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

